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 Abstract 
 The classification of neuroendocrine neoplasms (NENs) has been evolving steadily over the last de-
cades. Important prognostic factors of NENs are their proliferative activity and presence/absence of 
necrosis. These factors are reported in NENs of all body sites; however, the terminology as well as the 
exact rules of classification differ according to the location of the primary tumor. Only in gastroen-
teropancreatic (GEP) NENs a formal grading is performed. This grading is based on proliferation as-
sessed by the mitotic count and/or Ki-67 proliferation index. In the lung, NEN grading is an intrinsic 
part of the tumor designation with typical carcinoids corresponding to neuroendocrine tumor (NET) 
G1 and atypical carcinoids to NET G2; however, the presence or absence of necrotic foci is as impor-
tant as proliferation for the differentiation between typical and atypical carcinoids. Immunohisto-
chemical markers can be used to demonstrate neuroendocrine differentiation. Synaptophysin and 
chromogranin A are, to date, the most reliable and most commonly used for this purpose. Beyond 
this, other markers can be helpful, for example in the situation of a NET metastasis of unknown pri-
mary, where a hormonal profile or a panel of transcription factors can give hints to the primary site. 
Many immunohistochemical markers have been shown to correlate with prognosis but are not used 
in clinical practice, for example cytokeratin 19 and KIT expression in pancreatic NETs. There is no 
predictive biomarker in use, with the exception of somatostatin receptor (SSTR) 2 expression for pre-
dicting the amenability of a tumor to in vivo SSTR targeting for imaging or therapy. 
 © 2015 S. Karger AG, Basel 
 Classification of Neuroendocrine Neoplasms in the Gastroenteropancreatic System 
 The histological diagnosis of neuroendocrine neoplasms (NENs) is based on morpho-
logical criteria and is confirmed by immunohistochemical staining. NENs are subdi-
vided into well-differentiated tumors and poorly differentiated carcinomas, accord-
ing to their histomorphologic appearance. 
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 Well-Differentiated Neuroendocrine Tumors 
 Well-differentiated neuroendocrine tumors (NETs) are usually solitary, well-demar-
cated tumors which harbor a broad spectrum of possible growth patterns. Most com-
monly they show a solid, trabecular, gyriform or glandular pattern; less frequently 
they have a spindle cell, angiomatous, papillary or rhabdoid morphology  [1, 2] . Oc-
casionally, pancreatic NETs display cystic changes  [3, 4] . 
 The tumor cells are usually monomorphous with round to oval, centrally located 
nuclei and finely dispersed chromatin (so called ‘salt and pepper’); however, they can 
also  exhibit a striking variation in nuclear size and chromatin density. The cytoplasm 
has a granular, often eosinophilic aspect. Clear cell changes occur due to the storage 
of lipids  [5] .
 The extent of the stromal component is very variable. The grading of gastroen-
teropancreatic (GEP)-NETs is either based on the mitotic count or on immunohisto-
chemistry for Ki-67  [1, 6] . Mitoses are counted on hematoxylin and eosin (HE) stain-
ing in an area of 2 mm 2 in the area of highest mitotic count. The recommended Ki-67 
antibody for assessment of the proliferation index is the clone MIB1. The proliferative 
index is determined in 2,000 tumor cells in the area of highest density of positive nu-
clear staining (the ‘hot spot’) with at least a 400-fold magnification ( table 1 ).
 Well-differentiated NETs are subdivided into two subgroups according to their 
proliferative activity. G1 NETs have a low proliferative activity (<2 mitoses/2 mm 2 ; 
MIB1  ≤ 2%) and an indolent clinical course with a prolonged survival. G2 NETs have 
an intermediate proliferative activity ( ≥ 2–20 mitoses/2 mm 2 ; MIB1 3–20%) and ad-
verse outcome in comparison to G1 tumors, although they also have a prolonged 
clinical course  [7, 8] . From a biological point of view, the actual strict separation into 
two prognostic groups can be questioned and in fact it seems that there might be a 
more gradual increase of the risk of malignancy with increase of the Ki-67 index  [9] . 
 Poorly Differentiated Neuroendocrine Carcinomas 
 Poorly differentiated neuroendocrine carcinomas (NECs) are characterized by a high 
degree of pleomorphism, irregular nuclei and hyperchromasia. The growth pattern is 
predominantly sheet-like or diffuse. Mitoses are frequently found as well as extensive 
geographic necrosis  [5] . 
 GEP-NECs  [1, 6] have frequent mitoses, by definition more than 20 per 2 mm 2 , 
and/or high proliferative indices of >20%, although most carcinomas exceed these 
Table 1.  Grading according to Rindi et al. [7] and UICC/AJCC 2010
Grade Mitotic count (2 mm2) Ki-67, %
G1 <2 ≤2
G2 2–20 3–20
G3 >20 >20
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thresholds by far. They are further subdivided into small and large cell NECs accord-
ing to the size of their nuclei. Large cells are defined by a nuclear size of >3 lympho-
cytes. GEP-NECs are high-grade carcinomas with a rapid progression and short over-
all survival.
 Mixed Adenoneuroendocrine Carcinoma 
 A mixed adenoneuroendocrine carcinoma (MANEC) is a neoplasm consisting of an 
exocrine and an endocrine component. By definition, each component should com-
prise at least 30% of the tumor volume, otherwise the tumor is referred to as adeno-
carcinoma with partial neuroendocrine differentiation  [10] . An adenocarcinoma 
component is by far the most common for the exocrine element. An exception is rep-
resented by esophageal and anal MANEC, in which a squamous differentiation can 
also be found  [11] . Each component should be graded separately, with the adenocar-
cinoma according to the guidelines for conventional adenocarcinomas of the affected 
organ, whereas the neuroendocrine component is graded according to the guidelines 
for GEP-NETs  [11] . 
 TNM Staging System 
 For GEP-NENs there are currently two staging systems in use, namely the UICC and 
the European Neuroendocrine Tumor Society (ENETS) systems  [12, 13] . With the 
exception of pancreatic and appendiceal NETs, both systems are identical. While 
there are no data available yet for appendiceal NETs, for pancreatic NETs the ENETS 
staging system has repeatedly been shown to be superior in discriminating between 
prognostically meaningful different stages  [7, 14–17] . To ensure the comparability of 
data and avoid confusion, both staging systems should be reported  [18] . 
 Classification in the Lung, Thymus and Genitourinary Tract 
 The nomenclature of pulmonary and thymic NENs differs from GEP-NENs. For 
these primary localizations, the term carcinoid is still in use. Carcinoids are distin-
guished from poorly differentiated NECs. Carcinoids correspond to well-differenti-
ated NETs and are composed of bland, monomorphic cells. They show so-called dif-
ferentiated growth patterns as in GEP-NETs. They are further subdivided according 
to the WHO classification (2004) into typical (TC) and atypical (AC) carcinoids; 
these groups show many similarities to G1 and G2 GEP-NETs, although they are not 
identical. 
 Typical Carcinoid 
 Carcinoid tumors share the same morphological criteria as well-differentiated NETs 
in other organ sites. Macroscopically, they are well-demarcated, tan to yellow tu-
mors, often associated with bronchial mucosa. The histological diagnosis is based 
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on their cytological criteria and growth pattern. Monomorphic tumor cells with 
round to oval nuclei, finely dispersed chromatin and a moderate amount of eosino-
philic cytoplasm are characteristic. The neoplastic cells often grow in a nested, tra-
becular or solid fashion. TC by definition have less than 2 mitoses per 2 mm 2 and 
no necrosis. 
 Atypical Carcinoid 
 By definition, AC have 2–10 mitoses per 2 mm 2 or necrosis. The necrotic areas are 
usually punctate. The morphological growth pattern and cytology are identical to 
TC. 
 Poorly Differentiated NECs 
 Pulmonary, thymic and urogenital NECs have more than 10 mitoses per 2 mm 2 , al-
though in most cases they exceed this number by far and show more than 50 mitoses 
per 2 mm 2 . They do not show the differentiated growth patterns of NETs, but instead 
have a solid or sheet-like growth and frequently exhibit geographic necrosis. Also, for 
pulmonary NECs, a further subdivision into small and large cell variants correspond-
ing to their nuclear size is recommended, with small cell variants having a cell size 
corresponding to less than three lymphocytes. Evaluation of the Ki-67 proliferative 
activity by MIB1 staining, which is an integral part of the assessment in GEP-NETs is, 
at least to date, not compulsory, although it seems to bear additional prognostic im-
plications  [19] . 
 TNM Staging System 
 Pulmonary NENs are classified according to the 7th edition of the UICC/AJCC  [6] as 
lung cancer, even if the prognostic value of this system has never been proven useful 
for NENs. Currently, there is also no specific TNM staging system for thymic and 
urogenital NENs. 
 Immunohistochemistry 
 Immunohistochemical Markers to Confirm Neuroendocrine Differentiation 
 Depending on the site of the tumor and the guideline used, immunohistochemistry is 
useful/mandatory to confirm the neuroendocrine differentiation. Today the most 
commonly used markers are synaptophysin and chromogranin A, which both have a 
cytoplasmic staining pattern. Chromogranin A is a component of large secretory 
granules. Its expression level depends on the number of secretory granules  [20] ; there-
fore, poorly differentiated NECs often show only focal staining or even a lack immu-
nohistochemical positivity for chromogranin A  [21] . 
 Synaptophysin is a membrane protein of small vesicles of neuroendocrine 
cells  [22] . It has a lower specificity but a higher sensitivity for neuroendocrine differ-
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entiation in comparison to chromogranin A. It is more likely to be preserved in poor-
ly differentiated NENs.
 Beyond this, neuron-specific enolase, CD56/NCAM and PGP9.5 are additional 
markers of neuroendocrine differentiation. Due to their lack of specificity their use is 
not recommended anymore  [21] .
 Immunohistochemical Markers to Indicate the Primary Site 
 In the case of metastases, it is a challenge to identify the origin of the primary tumor 
on morphological grounds alone. A few markers have been shown to provide 
i nformation regarding the primary site in such circumstances. They encompass 
 either  peptide hormones, enzymes involved in their biogenesis or transcription 
 factors. 
 The vesicular monoamine transporter 2 (VMAT2) is expressed in gastric NENs 
 [10] . A positive staining for serotonin suggests primarily an ileal origin, but can also 
be found in NETs from the jejunum or appendix and less frequently from other sites, 
such as the lung or pancreas  [21] . Expression of somatostatin and gastrin points to-
wards a duodenal or pancreatic primary. Cytoplasmic staining for NESP-55 (neuro-
endocrine secretory protein-55) seems to be restricted to tumors of pancreatic (or 
adrenal) origin  [23] , and the immunohistochemical expression of insulin, glucagon 
and pancreatic polypeptide points towards a pancreatic primary.
 The transcription factor CDX2 is expressed in intestinal NETs. Nuclear staining 
for islet 1 strongly suggests a pancreatic origin  [24] . Conflicting results have been pub-
lished concerning the reliability of thyroid transcription factor 1 (TTF-1) for pulmo-
nary NETs. Although a subset of carcinoids expresses this marker, there are other 
NETs, including medullary thyroid carcinoma, which express TTF-1. Therefore, im-
munohistochemical results must be interpreted with caution  [24, 25] . Interestingly, 
80–100% of rectal NETs express prostate-specific acid or prostate-specific acid phos-
phatase  [26] .
 While all the above markers are of use in well-differentiated NETs, this is not the 
case for poorly differentiated NECs  [27] . Immunohistochemistry here can be of help 
in the differential diagnosis between Merkel cell carcinomas and cutaneous metasta-
ses of pulmonary NECs: while Merkel cell carcinomas are usually positive for CK20, 
typically with a dot-like staining pattern, they are normally negative for TTF-1. In 
contrast, pulmonary NECs should be negative for CK20 and show TTF-1 expression 
in a proportion of cases.
 Immunohistochemical Predictive Markers 
 The expression of somatostatin receptors (SSTR) is a typical feature of well-differen-
tiated NENs with high expression levels, especially in tumors of GEP origin. In the 
absence of a preoperative SSTR imaging, immunohistochemistry is the best way to 
determine a potential receptor expression. Immunohistochemistry for SSTR subtype 
2a has been shown repeatedly to be a reliable method by which to detect high receptor 
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expression levels. At least a moderate (noncircumferential) membranous staining 
 [28] in at least 20% of tumor cells  [29] correlates with in vivo SSTR-2 measurement. 
Markers predicting response to the wide range of therapeutic compounds applied to 
NENs have not yet been described. 
 Immunohistochemical Prognostic Markers 
 Estimation of the aggressiveness of NENs is a challenge since morphological 
 characteristics, in contrast to other neoplasms, are of limited use. Proliferative activ-
ity measured by MIB1 staining has been proven in many studies to correlate with out-
come. Beyond this, positive staining for cytokeratin 19 and KIT have been proven to 
be associated with an adverse outcome in pancreatic NENs  [30, 31] . 
 Important Organ-Specific Features 
 Gastric NENs 
 So-called ECL (enterochromaffin-like) cell carcinoids are the most frequent type of 
gastric NETs. They share phenotypes with normal ECL cells, such as the expression 
of VMAT2  [32] . Depending on the genetic and biological setting, three different types 
of gastric ECL cell carcinoids are defined. Even if the tumor tissue cannot be discrim-
inated morphologically, the prognosis of ECL cell carcinoids and, therefore, the ther-
apeutic approach depends strongly on this context. Examining biopsies of the sur-
rounding nonneoplastic mucosa allows the pathologist to find hints to discriminate 
the three forms ( table 2 ). 
 The most frequent form, type 1 ECL cell carcinoid  [33] , is associated with chron-
ic atrophic gastritis. Hypergastrinemia is a driving factor of tumor development. 
ECL cell carcinoids are multiple and are accompanied by different stages of 
 preneoplastic ECL cell lesions: linear, micronodular, adenomatoid hyperplasia and 
microcarcinoid. Recognition of the surrounding chronic atrophic gastritis, togeth-
er with clinical/laboratory diagnosis of CAG, is diagnostic. The stages of preneo-
plastic lesions predict the risk of recurrence of type 1 ECL-cell carcinoids after en-
doscopic resection  [34] . Most of these NETs are G1 and T1 (according to 
Table 2.  Discrimination between different types of gastric ECL cell carcinoids
Type 1 Type 2 Type 3
Gastric mucosa Chronic atrophic gastritis Hyperplasia of parietal cells Normal
ECL cell hyperplasia
(linear or micronodular)
ECL cell hyperplasia
Multiple tumors
Multiple tumors
Grading G1 G1–2 Often G3
Papotti M, de Herder WW (eds): Neuroendocrine Tumors: A Multidisciplinary Approach.
Front Horm Res. Basel, Karger, 2015, vol 44, pp 104–114 ( DOI: 10.1159/000382135 )
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
19
8.
14
3.
58
.1
 - 
12
/7
/2
01
5 
1:
18
:2
4 
PM
110  Blank · Schmitt · Perren 
 endoultrasonography), and in such cases therapy guidelines recommend endoscop-
ic resection  [35, 36] .
 Type 2 ECL cell carcinoids are associated with Zollinger-Ellison syndrome in the 
setting of a multiple endocrine neoplasia type 1 (MEN1). This rare variant is associ-
ated with hyperplasia of parietal cells in the surrounding gastric mucosa and is clini-
cally more aggressive  [35] . Biologically, these tumors have a loss of the wild-type 
MEN1 allele; however, this is not used for clinical diagnosis.
 Type 3 ECL cell carcinoids of the stomach arise de novo and are solitary tumors. 
Frequently, they are poorly differentiated and show a high Ki-67 index corresponding 
to NEC G3.
 All ECL cell carcinoids are characterized by the expression of VMAT2  [32] . The 
clinical significance of endocrine product expression, such as ghrelin or serotonin, in 
gastric NETs is unknown.
 Duodenal, Jejunal and Ileal NENs 
 The predominant proportion of duodenal NENs are well differentiated with only 
1–3% NECs  [35] . Usually, they are small and solitary lesions. In 6% of cases they are 
associated with MEN1 and multiple tumors in particular should raise the suspicion of 
this hereditary condition, whereas the majority of NETs arising in a periampullary 
localization are associated with neurofibromatosis type 1  [35] . Ampullary NETs are 
often somatostatin-producing tumors, which characteristically contain psammoma 
bodies  [35] . 
 Jejunal and ileal NENs harbor a relatively high risk for an aggressive clinical course. 
In most cases, lymph node or distant metastases are present at the time of diagnosis 
 [37] . Jejunal and ileal NENs only rarely arise in a hereditary setting  [38] .
 Appendiceal NENs 
 Appendiceal NENs are the second most common neuroendocrine neoplasms, most 
of them being located at the tip of the appendix and found incidentally during appen-
dectomy for appendicitis. Less than 5% of appendiceal NENs are MANECs, or so-
called goblet cell carcinoids. Tumor cells have a signet-ring cell appearance with in-
tracytoplasmic mucin and compressed nuclei at the periphery. These mixed tumors 
have been shown to be associated with an adverse clinical outcome compared to stage-
matched ordinary NETs. Often they diffusely infiltrate into the appendiceal fat and 
show extensive perineural invasion (see also the section ‘Mixed Adenoneuroendo-
crine Carcinoma’)  [37, 39] . 
 Colonic and Rectal NENs 
 It is important to differentiate between colonic and rectal NENs as these neoplasms 
differ markedly from each other. The most common localization of colonic NENs is 
the cecum. They are often associated with adenomas or adenocarcinomas. In most 
cases of colonic NENs, metastases are present at the time of diagnosis, probably due 
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to a long asymptomatic course, and therefore have the worst prognosis among GEP-
NETs  [24, 40] . 
 In contrast, rectal NENs are more frequently diagnosed in a localized stage and are 
associated with a better prognosis. They often lack immunohistochemical expression 
of chromogranin A, while the expression of synaptophysin is retained  [21] . Colonic 
and rectal NENs are not associated with hereditary disease.
 Pancreatic NENs 
 Most pancreatic NENs are well-differentiated tumors. The recognizable growth pat-
terns correspond to those seen in well-differentiated NENs. Beyond this, insulinomas 
often exhibit amyloid deposits, while psammoma bodies are frequently found in so-
matostatinomas  [5] . 
 Hormonal markers ( table 3 ) are available and frequently expressed in pancreatic 
NETs. Their expression level does not imply information about the functional status. 
Functional tumors are exclusively defined by clinical symptoms due to inadequate hor-
monal secretion. Pancreatic NETs with a size <0.5 cm are classified as microadenomas. 
Pancreatic NETs can occur in the context of hereditary disease, with MEN1 being the 
most common, followed by von Hippel-Lindau disease and tuberous sclerosis  [41] .
 Lung NENs 
 In contrast to other primary localizations, poorly differentiated NECs, which account 
for 20% of all lung tumors, are much more common than well-differentiated NETs, 
which represent 2%  [42] . Small cell lung cancer (poorly differentiated NEC of the 
lung, small cell type) is heavily associated with smoking. Among carcinoids, TC forms 
are 8- to 10-times more frequent than AC. 
 A precondition, which has been shown to have the potential to progress to carci-
noid tumors, is the so-called diffuse idiopathic pulmonary neuroendocrine cell hyper-
plasia. This is a very rare condition, which is defined by a diffuse proliferation of neu-
roendocrine cells, either in a linear or nodular fashion, in an otherwise unremarkable 
lung. If these aggregates of neuroendocrine cells extend beyond the basal membrane 
Table 3.  Immunohistochemical hormonal markers with typical primary sites
Protein Organ
Insulin Pancreas
Glucagon Pancreas
Somatostatin Pancreas/duodenum
Gastrin Duodenum/pancreas
Vasoactive intestinal polypeptide Pancreas
Pancreatic polypeptide Pancreas
Serotonin Small intestine/pancreas
Adrenocorticotropic hormone Pituitary/lung/pancreas
Calcitonin Thyroid/pancreas/small intestine
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they are classified as tumorlets, which, by definition, are <5 mm in diameter. If the 
tumor is 0.5 cm or larger, it is classified as carcinoid. In 5% of the cases, carcinoid tu-
mors arise in the context of MEN1  [43] .
 Thymic NENs 
 NETs of the thymus are rare tumors. They may arise in the setting of an inherited MEN1 
syndrome. It is important to notice that, by definition, the whole tumor population 
must display an endocrine phenotype  [44] . They are classified analogs to pulmonary 
NETs and the terms TC and AC are used for the well-differentiated thymic types (see 
also the section ‘Lung NENs’). However, compared to the lung, a larger proportion of 
thymic NETs are categorized in the group of AC. Like their pulmonary counterparts, 
poorly differentiated thymic NENs are separated into small cell and large cell NECs. 
 Genitourinary NENs 
 The classification of genitourinary NENs is similar to that of pulmonary NENs. The well-
differentiated forms arise most frequently in the ovary as ovarian carcinoids and can be 
associated with teratomas. Poorly differentiated NECs are reported in the ovaries and in 
the uterine cervix and endometrium, as well as in the urinary bladder and prostate. 
 Merkel Cell Carcinoma 
 The histological appearance of Merkel cell carcinomas corresponds to poorly differ-
entiated NECs. Morphologically, Merkel cell carcinoma belongs to the group of small 
round blue cell tumors, which refers to the small nuclei size with sparse cytoplasm. 
There is no grading system for Merkel cell carcinomas. Several histopathologic fea-
tures, such as a diffuse growth pattern, infiltration of the subcutis and pronounced 
lymphocytic infiltrate have been associated with an adverse outcome  [45] . 
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